Provided by Tiger Fintech (Singapore) Pte. Ltd.

Black Diamond Therapeutics, Inc.

1.61
-0.0600-3.59%
Pre-market: 1.56-0.0500-3.11%05:41 EDT
Volume:1.27M
Turnover:2.02M
Market Cap:91.23M
PE:-1.27
High:1.65
Open:1.64
Low:1.55
Close:1.67
Loading ...

Buy Rating on Black Diamond Therapeutics: Promising Phase 2 Results for BDTX-1535 in NSCLC Treatment

TIPRANKS
·
24 Sep 2024

EUROPE RESEARCH ROUNDUP-Costco Wholesale, McKesson, Starbucks

Reuters
·
24 Sep 2024

Black Diamond Therapeutics Inc : Piper Sandler Raises Target Price to $15 From $12

THOMSON REUTERS
·
24 Sep 2024

Black Diamond Theraptcs Is Maintained at Overweight by Piper Sandler

Dow Jones
·
24 Sep 2024

Black Diamond Therapeutics' Lead Drug Candidate Shows Initial Anti-tumor Activity In Certain Type Of Lung Cancer Resistant To AstraZeneca's Drug

Benzinga
·
23 Sep 2024

Sector Update: Health Care

MT Newswires Live
·
23 Sep 2024

Black Diamond Therapeutics Reports 'Robust Anti-Tumor Activity' in Phase 2 BDTX-1535 Trial for Cell Lung Cancer

MT Newswires Live
·
23 Sep 2024

Black Diamond Therapeutics Shares Jump on Positive Data for Cancer Treatment

Dow Jones
·
23 Sep 2024

Top Premarket Gainers

MT Newswires Live
·
23 Sep 2024

Black Diamond Therapeutics Inc - Initial Results of Bdtx-1535 in First-Line Nsclc Patients With Non-Classical Egfr Mutations Expected Q1 2025

THOMSON REUTERS
·
23 Sep 2024

Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance Mutations

GlobeNewswire
·
23 Sep 2024

Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC

GlobeNewswire
·
22 Sep 2024